Please login to the form below
LentiGlobin
This page shows the latest LentiGlobin news and features for those working in and with pharma, biotech and healthcare.
bluebird bio to restart marketing of Zynteglo in EU after previous suspension
Earlier this year, bluebird voluntarily withdrew marketing of Zynteglo (betibeglogene autotemcel) in the EU after safety events relating to LentiGlobin for sickle cell disease (SCD) were reported. ... In March bluebird reported that it is ‘very
Latest news
-
bluebird bio lodges counterclaim against Spark Therapeutics
bluebird bio is developing its gene therapy LentiGlobin for sickle cell disease, which currently has an orphan drug designation as well as fast track and rare paediatric disease designations from the
-
MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’
In a statement, bluebird bio said that if LentiGlobin is approved it could become the first one-time treatment for the rare blood disorder in the UK. ... These studies were relaunched earlier this month after the US Food and Drug Administration (FDA)
-
FDA lifts clinical hold on bluebird bio’s LentiGlobin studies
The US Food and Drug Administration (FDA) has lifted the clinical holds on numerous studies evaluating its gene therapy LentiGlobin for sickle cell disease (SCD) and beta-thalassemia. ... 1/2 HGB-206 study of LentiGlobin (betibeglogene autotemcel;
-
bluebird bio aiming to separate business units by year-end
In April, bluebird bio also announced that it is anticipating a potential lift of all clinical holds on its LentiGlobin gene therapy for sickle cell disease (SCD) following the re-classification ... bluebird bio also previously reported that it is
-
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111) to market.
More from news
Approximately 9 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia. ... The initial studies for LentiGlobin in
-
Drug launches to watch in 2019
7. LentiGlobin TDT – a gene therapy first for Europe. Gene therapy company Bluebird Bio is on course to gain approval for its first product this year – and Europe is expected to ... The Cambridge, Massachusetts-based firm filed its gene therapy
-
Bluebird Bio: on the cusp of a gene therapy revolution
The Cambridge, Mass-based company is set to file the first of its four candidates, LentiGlobin TDT, a gene therapy for patients with the rare blood disorder beta thalassemia, by the ... Pharmaceutical Market Europe spoke to Bluebird’s CEO Nick Leschly
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
Grace Communications
We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
